0001628280-25-050315 | 10-Q | XBRL Viewer

Print Document

Fair Value Measurements - Schedule of assets and liabilities measured at fair value on recurring basis (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Liabilities
Warrant liabilities	$ 139	$ 488
Recurring \| Private Placement Warrants
Liabilities
Warrant liabilities	139	488
Recurring \| Money market funds
Assets
Cash, cash equivalents, and restricted cash:	126,580	284,462
Recurring \| Level 1 \| Private Placement Warrants
Liabilities
Warrant liabilities	0	0
Recurring \| Level 1 \| Money market funds
Assets
Cash, cash equivalents, and restricted cash:	126,580	284,462
Recurring \| Level 2 \| Private Placement Warrants
Liabilities
Warrant liabilities	0	0
Recurring \| Level 2 \| Money market funds
Assets
Cash, cash equivalents, and restricted cash:	0	0
Recurring \| Level 3 \| Private Placement Warrants
Liabilities
Warrant liabilities	139	488
Recurring \| Level 3 \| Money market funds
Assets
Cash, cash equivalents, and restricted cash:	$ 0	$ 0

Revenue

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Revenue

Net sales consist of the sale of products to retail and wholesale customers through e-commerce and distributor sales. The Company generates revenue through manufacturing and selling its patented hydradermabrasion delivery systems (“Delivery Systems”). In conjunction with the sale of Delivery Systems, the Company also sells single-use tips, solutions, and serums used to provide a Hydrafacial treatment (collectively “Consumables”). Original Consumables are sold solely and exclusively by the Company (and from authorized retailers) and are available for purchase separately from the purchase of Delivery Systems. For both Delivery Systems and Consumables, revenue is recognized upon transfer of control to the customer, which generally takes place at the point of shipment.

Net sales disaggregated by major product line were as follows for the periods indicated:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2025		2024		2025		2024
Net Sales
Delivery Systems	$	20,819	$	27,613	$	63,394	$	98,605
Consumables	49,836		51,189		155,028		152,194
Total net sales	$	70,655	$	78,802	$	218,422	$	250,799

Net sales by geographic region were as follows for the periods indicated:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2025		2024		2025		2024
Americas	$	48,263	$	51,878	$	146,568	$	159,935
Europe, the Middle East and Africa	16,056		16,095		49,465		54,428
Asia-Pacific	6,336		10,829		22,389		36,436
Total net sales	$	70,655	$	78,802	$	218,422	$	250,799

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash, cash equivalents, and restricted cash	$ 219,397	$ 370,063
Accounts receivable, net of allowances for estimated credit losses of $7,429 and $9,597 at September 30, 2025 and December 31, 2024, respectively	22,206	27,643
Inventories	56,146	69,113
Income tax receivable	3,186	818
Prepaid expenses and other current assets	7,432	9,487
Total current assets	308,367	477,124
Property and equipment, net	3,053	5,978
Right-of-use assets, net	13,612	13,590
Intangible assets, net	37,981	47,512
Goodwill	126,497	123,499
Deferred income tax assets, net	985	3,894
Other assets	13,141	14,086
TOTAL ASSETS	503,636	685,683
Current liabilities:
Accounts payable	17,294	21,941
Accrued payroll-related expenses	18,759	17,636
Lease liabilities, current	5,041	5,147
Income tax payable	1,495	3,426
Other accrued expenses	19,315	20,002
Total current liabilities	61,904	68,152
Lease liabilities, non-current	10,551	10,813
Deferred income tax liabilities, net	112	396
Warrant liabilities	139	488
Convertible senior notes, net	363,388	552,198
Other long-term liabilities	1,882	1,833
Total liabilities	437,976	633,880
Commitments (Note 6)
Stockholders’ equity:
Class A Common Stock, $0.0001 par value; 320,000,000 shares authorized; 127,301,264 and 124,924,185 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	13	12
Additional paid-in capital	576,802	566,709
Accumulated other comprehensive loss	(1,775)	(6,953)
Accumulated deficit	(509,380)	(507,965)
Total stockholders’ equity	65,660	51,803
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 503,636	$ 685,683

Share-Based Compensation - Narrative (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2025 USD ($)	Sep. 30, 2025 USD ($)
Share-Based Payment Arrangement [Abstract]
Share-based payment arrangement, forfeited	$ 2.6	$ 5.1
Unrecognized compensation cost	$ 19.4	$ 19.4
Unrecognized compensation cost, period for recognition (in years)		1 year 10 months 24 days

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Allowances for doubtful accounts	$ 7,429	$ 9,597
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	320,000,000	320,000,000
Common stock, shares issued (in shares)	127,301,264	124,924,185
Common stock, shares outstanding (in shares)	127,301,264	124,924,185

Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Sales and VAT tax payables	$ 2,852	$ 5,244
Accrued interest	7,624	1,743
Royalty liabilities	1,504	1,897
Deferred revenue	534	2,375
Other	6,801	8,743
Total other accrued expenses	$ 19,315	$ 20,002

Net Loss Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Earnings Per Share Computation (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
2026 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	3,919,522	17,559,686	0	0
2028 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	87,412,575	0	87,412,575	0
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	10,749,645	7,827,861	10,749,645	7,827,861
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	2,540,845	3,571,820	2,540,845	3,571,820
PSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	1,465,343	2,302,162	1,465,343	2,302,162

Commitments and Contingencies (Details)	Jan. 16, 2024 competingMotion
Securities Class Action
Loss Contingencies [Line Items]
Loss contingency, number of competing motions	3

Description of Business (Details) - $ / shares	Sep. 30, 2025	Dec. 31, 2024	May 04, 2021
Business Combination [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Hydrafacial
Business Combination [Line Items]
Percentage of voting interests acquired (as a percent)			100.00%
Merger Sub II
Business Combination [Line Items]
Percentage of voting interests acquired (as a percent)			100.00%
Hydrafacial And Subsidiaries
Business Combination [Line Items]
Percentage of voting interests acquired (as a percent)			100.00%

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 386	$ 1,948	$ 285	$ 936
Gross unrecognized tax benefits	$ 1,500		$ 1,500		$ 1,200

Property and Equipment, net (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation and amortization	$ (25,063)	$ (25,500)
Property and equipment, net	3,053	5,978
Total property and equipment
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	28,116	31,478
Leasehold improvements
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	10,965	12,019
Machinery and equipment
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	$ 5,076	7,076
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)	2 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	$ 5,954	6,096
Furniture and fixtures \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)	2 years
Furniture and fixtures \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)	7 years
Computers and equipment
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	$ 5,302	5,496
Computers and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)	3 years
Computers and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)	5 years
Tooling
Property, Plant and Equipment [Line Items]
Useful life (years)	5 years
Plant and equipment, including finance lease, gross	$ 732	732
Autos and trucks
Property, Plant and Equipment [Line Items]
Useful life (years)	5 years
Plant and equipment, including finance lease, gross	$ 61	59
Construction in progress
Property, Plant and Equipment [Line Items]
Plant and equipment, including finance lease, gross	$ 26	$ 0

Related-Party Transactions (Details) - Related Party	May 04, 2021 demand tradingDay $ / shares shares
Related Party Transaction [Line Items]
Stock issued upon conversion (in shares) \| shares	11,500,000
Registration rights agreement, filing timeline	60 days
Registration rights agreement, number of demands for registration allowed \| demand	2
Private Placement Warrants
Related Party Transaction [Line Items]
Reverse recapitalization, contingent consideration, earnout period	30 days
Vesper Founders
Related Party Transaction [Line Items]
Reverse recapitalization, contingent consideration, earnout period	1 year
Reverse recapitalization, contingent consideration, stock price trigger (in dollars per share) \| $ / shares	$ 12.00
Reverse recapitalization, contingent consideration, threshold days	20
Reverse recapitalization, contingent consideration, consecutive threshold days	30
Reverse recapitalization, contingent consideration, commencement period	150 days
LCP
Related Party Transaction [Line Items]
Reverse recapitalization, threshold percentage to designate one director (as a percent)	10.00%
Reverse recapitalization, threshold percentage to designate two directors (as a percent)	15.00%
Reverse recapitalization, threshold percentage to designate three directors (as a percent)	40.00%
Reverse recapitalization, threshold percentage to designate one director on board (as a percent)	10.00%

Balance Sheet Components - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Warranty reserve	$ 2	$ 4
Restricted cash	$ 2	$ 2

Share-Based Compensation - Schedule of Share-Based Payment Arrangement, Activity (Details)	9 Months Ended
	Sep. 30, 2025 $ / shares shares
RSU Shares
Shares
Outstanding, beginning balance (in shares) \| shares	7,254,391
Granted (in shares) \| shares	10,396,409
Vested (in shares) \| shares	(2,907,129)
Forfeited (in shares) \| shares	(3,994,026)
Outstanding, ending balance (in shares) \| shares	10,749,645
Weighted Average Grant Date Fair Value
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 4.56
Granted (in dollars per share) \| $ / shares	1.34
Vested (in dollars per share) \| $ / shares	4.99
Forfeited (in dollars per share) \| $ / shares	2.61
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 2.06
PSUs
Shares
Outstanding, beginning balance (in shares) \| shares	1,237,822
Granted (in shares) \| shares	1,676,134
Vested (in shares) \| shares	(441,558)
Forfeited (in shares) \| shares	(1,007,055)
Outstanding, ending balance (in shares) \| shares	1,465,343
Weighted Average Grant Date Fair Value
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 5.93
Granted (in dollars per share) \| $ / shares	2.12
Vested (in dollars per share) \| $ / shares	3.11
Forfeited (in dollars per share) \| $ / shares	4.09
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 3.69

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss	$ (1,415)	$ (18,768)
Adjustments to reconcile net loss to net cash from operating activities
Share-based compensation	11,239	20,846
Amortization of intangible assets	13,513	15,314
Depreciation of property and equipment	3,204	8,486
Amortization of other assets	3,281	3,321
Amortization of debt issuance costs	2,621	2,532
Inventory write-down	3,643	22,704
Provision for estimated credit losses	1,933	5,135
Change in fair value of warrant liabilities	(349)	(2,997)
Gain on exchange and repurchases of convertible senior notes, net	(18,089)	(33,411)
Deferred income taxes	2,893	(250)
Other, net	(2,679)	9,938
Changes in operating assets and liabilities:
Accounts receivable	4,769	13,348
Inventories	11,114	(7,468)
Prepaid expenses, other current assets, and income tax receivable	(110)	7,956
Accounts payable, accrued expenses, and income tax payable	(7,117)	(39,501)
Other, net	(6,162)	(7,523)
Net cash provided by (used for) operating activities	22,289	(338)
Cash flows from investing activities:
Cash paid for intangible assets	(3,617)	(5,250)
Cash paid for property and equipment	(164)	(682)
Net cash used for investing activities	(3,781)	(5,932)
Cash flows from financing activities:
Repurchase of 2026 Notes in connection with exchange	(392,583)	0
Issuance of 2028 Notes in connection with exchange, net	237,686	0
Repurchase of 2026 Notes	(18,372)	(156,082)
Payment of tax withholdings on vested stock awards	(1,145)	(1,489)
Net cash used for financing activities	(174,414)	(157,571)
Net change in cash, cash equivalents, and restricted cash	(155,906)	(163,841)
Effect of foreign currency translation on cash	5,240	(292)
Cash, cash equivalents, and restricted cash beginning of period	370,063	523,025
Cash, cash equivalents, and restricted cash end of period	$ 219,397	$ 358,892

Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Raw materials	$ 23,001	$ 26,019
Finished goods	33,145	43,094
Total inventories	$ 56,146	$ 69,113

New Accounting Pronouncements	9 Months Ended
New Accounting Pronouncements	Sep. 30, 2025
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements In December 2023, the Financial Standards Accounting Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its annual consolidated financial statement disclosures. In November 2024, the FASB issued ASU 2024-03 “Disaggregation of Income Statement Expenses” which expands interim and annual requirements to disclose about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, which was clarified in ASU 2025-01. The standard allows for early adoption of these requirements. The Company is currently evaluating the potential effect that the updated standard will have on its consolidated financial statement disclosures. In November 2024, the FASB issued ASU 2024-04 “Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments” which is intended to clarify requirements for determining whether certain settlements of convertible debt instruments, including convertible debt instruments with cash conversion features or convertible debt instruments that are not currently convertible, should be accounted for as an induced conversion. ASU 2024-04 is effective for annual periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements and related disclosures. In July 2025, the FASB issued ASU 2025-05 “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets” which simplifies the application of the current expected credit loss model for current accounts receivable and current contract assets under ASC 606. ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, with early adoption permitted, and should be applied prospectively. The Company is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements and related disclosures. In September 2025, the FASB issued ASU 2025-06 “Intangibles: Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software” which modernizes the accounting for internal-use software to current development practices, clarifies when to begin capitalizing costs, and enhances disclosure requirements. ASU 2025-06 is effective for interim and annual periods beginning after December 15, 2027, with early adoption permitted, and should be applied either prospectively, retrospectively, or under a modified prospective transition approach. The Company is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements and related disclosures.

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Debt Instrument [Line Items]
Unamortized debt issuance costs	$ (11,097)	$ (5,502)
Convertible senior notes, net	363,388	552,198
Convertible Debt \| 1.25% Convertible Senior Notes Due 2026
Debt Instrument [Line Items]
Long-term debt, gross	124,485	557,700
Convertible Debt \| 7.95% Convertible Senior Secured Notes due 2028
Debt Instrument [Line Items]
Long-term debt, gross	$ 250,000	$ 0

Fair Value Measurements - Narrative (Details) - Private Placement Warrants - $ / shares	Sep. 30, 2025	Dec. 31, 2024	Oct. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding (in shares)	7,000,000	7,000,000	9,333,333
Warrants, exercise price (in dollars per share)			$ 11.50
Class of warrant or right, expiration period (in years)			5 years

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Segment Information - Narrative (Details)	9 Months Ended
Segment Information - Narrative (Details)	Sep. 30, 2025 segment
Segment Reporting [Abstract]
Number of operating segments	1
Number of reportable segments	1

Long-term Debt - Narrative (Details)				9 Months Ended
Long-term Debt - Narrative (Details)	May 27, 2025 $ / shares	May 21, 2025 USD ($)	Sep. 14, 2021 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
Repurchase of convertible senior notes				$ 18,372,000	$ 156,082,000
Gain on extinguishment of debt				18,089,000	33,411,000
Convertible Debt
Debt Instrument [Line Items]
Gain on extinguishment of debt		$ 16,600,000
Unamortized debt issuance costs		3,100,000
Debt instrument, other fees		900,000
Convertible Debt \| Level 2
Debt Instrument [Line Items]
Estimated fair value of notes				390,900,000		$ 446,200,000
Long-term debt, gross				374,500,000		557,700,000
1.25% Convertible Senior Notes Due 2026 \| Convertible Debt
Debt Instrument [Line Items]
Face amount			$ 750,000,000
Stated interest rate (as a percent)			1.25%
Accordion feature, settlement period			13 days
Accordion feature, increase limit			$ 100,000,000
Debt instrument, repurchased face amount		150,100,000
Exchanged and repurchased principal amount		413,200,000
Amount of debt exchanged		$ 263,200,000
Debt instrument, redemption price (as a percent)		95.00%
Debt instrument, repurchase amount		$ 142,600,000
Debt instrument, other fees				900,000
Long-term debt, gross				124,485,000		557,700,000
1.25% Convertible Senior Notes Due 2026 \| Convertible Debt \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument, repurchased face amount				0	0
1.25% Convertible Senior Notes Due 2026 \| Convertible Debt \| Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument, repurchased face amount				20,000,000	192,300,000
Repurchase of convertible senior notes				18,400,000	156,100,000
Gain on extinguishment of debt				1,500,000	33,400,000
Unamortized debt issuance costs				100,000	$ 2,800,000
7.95% Convertible Senior Secured Notes due 2028 \| Convertible Debt
Debt Instrument [Line Items]
Face amount		$ 250,000,000
Stated interest rate (as a percent)	7.95%	7.95%
Conversion ratio	0.3496503
Conversion price (in dollars per share) \| $ / shares	$ 2.86
Debt instrument, optional redemption, liquidity conditions satisfied, period prior to maturity date, threshold number of trading days	40 days
Payments of debt issuance costs				11,400,000
Long-term debt, gross				$ 250,000,000		$ 0

Related-Party Transactions	9 Months Ended
Related-Party Transactions	Sep. 30, 2025
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions Registration Rights Agreement In connection with the consummation of the Business Combination, on May 4, 2021, the Company entered into that certain Amended and Restated Registration Rights Agreement (the “Registration Rights Agreement”) with BLS Investor Group LLC and the Hydrafacial Stockholders. Pursuant to the terms of the Registration Rights Agreement, (i) any outstanding shares of Class A Common Stock or any other equity securities (including the Private Placement Warrants and including shares of Class A Common Stock issued or issuable upon the exercise of any other equity security) of the Company held by BLS Investor Group LLC (the “Sponsor”) or the Hydrafacial Stockholders (together, the “Restricted Stockholders”) as of the date of the Registration Rights Agreement or thereafter acquired by a Restricted Stockholder (including the shares of Class A Common Stock issued upon conversion of the 11,500,000 shares of Class B common stock (the “Founder Shares”) that were owned by the Sponsor and converted into shares of Class A Common Stock in connection with the Business Combination and upon exercise of any Private Placement Warrants) and shares of Class A Common Stock issued as earn-out shares to the Hydrafacial Stockholders and (ii) any other equity security of the Company issued or issuable with respect to any such share of Class A Common Stock by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise will be entitled to registration rights. The Registration Rights Agreement provides that the Company will, within 60 days after the consummation of the Business Combination, file with the SEC a shelf registration statement registering the resale of the shares of Class A Common Stock held by the Restricted Stockholders and will use its reasonable best efforts to have such registration statement declared effective as soon as practicable after the filing thereof, but in no event later than 60 days following the filing deadline. The Company filed such registration statement on July 19, 2021 and it was declared effective by the SEC on July 26, 2021. The Hydrafacial Stockholders are entitled to make up to an aggregate of two demands for registration, excluding short form demands, that the Company register shares of Class A Common Stock held by these parties. In addition, the Restricted Stockholders have certain “piggy-back” registration rights. The Company will bear the expenses incurred in connection with the filing of any registration statements filed pursuant to the terms of the Registration Rights Agreement. The Company and the Restricted Stockholders agree in the Registration Rights Agreement to provide customary indemnification in connection with any offerings of Class A Common Stock effected pursuant to the terms of the Registration Rights Agreement. Pursuant to the Registration Rights Agreement, the Sponsor agreed to restrictions on the transfer of its securities issued in the Company’s initial public offering, which (i) in the case of the Founder Shares is one year after the completion of the Business Combination unless (A) the closing price of the Class A Common Stock equals or exceeds $12.00 per share for 20 days out of any 30-trading-day period commencing at least 150 days following the Closing of the Business Combination or (B) the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of Class A Common Stock for cash, securities or other property, and (ii) in the case of the Private Placement Warrants and the respective Class A Common Stock underlying the Private Placement Warrants is 30 days after the completion of the Business Combination. The Sponsor and its permitted transferees will also be required, subject to the terms and conditions in the Registration Rights Agreement, not to transfer their Private Placement Warrants (as defined in the Registration Rights Agreement) or shares of Class A Common Stock issuable upon the exercise thereof for 30 days following the Closing. Investor Rights Agreement In connection with the consummation of the Business Combination, on May 4, 2021, the Company and LCP Edge Holdco, LLC entered into that certain Investor Rights Agreement (the “Investor Rights Agreement”). Pursuant to the Investor Rights Agreement, LCP has the right to designate a number of directors for appointment or election to the Company’s Board of Directors as follows: (i) one director for so long as LCP holds at least 10% of the outstanding Class A Common Stock, (ii) two directors for so long as LCP holds at least 15% of the outstanding Class A Common Stock, and (iii) three directors for so long as LCP holds at least 40% of the outstanding Class A Common Stock. Pursuant to the Investor Rights Agreement, for so long as LCP holds at least 10% of the outstanding Class A Common Stock, LCP will be entitled to have at least one of its designees represented on the compensation committee and nominating committee and corporate governance committee of the Company’s Board of Directors.

Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 158,135	$ 153,450
Accumulated Amortization	(120,154)	(105,938)
Net Carrying Value	37,981	47,512
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	91,629	91,629
Accumulated Amortization	(77,995)	(74,655)
Net Carrying Value	$ 13,634	$ 16,974
Developed technology \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	3 years	3 years
Developed technology \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	10 years	10 years
Capitalized software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 25,282	$ 22,983
Accumulated Amortization	(14,176)	(8,027)
Net Carrying Value	$ 11,106	$ 14,956
Capitalized software \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	3 years	3 years
Capitalized software \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years	5 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 19,031	$ 17,569
Accumulated Amortization	(16,746)	(13,696)
Net Carrying Value	$ 2,285	$ 3,873
Customer relationships \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years	5 years
Customer relationships \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	10 years	10 years
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 11,700	$ 11,674
Accumulated Amortization	(6,807)	(6,189)
Net Carrying Value	$ 4,893	$ 5,485
Estimated Useful Life (Years)	15 years	15 years
Non-compete agreement
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,905	$ 5,814
Accumulated Amortization	(3,455)	(2,605)
Net Carrying Value	$ 2,450	$ 3,209
Estimated Useful Life (Years)	3 years	3 years
Patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 4,588	$ 3,781
Accumulated Amortization	(975)	(766)
Net Carrying Value	$ 3,613	$ 3,015
Patents \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	3 years	3 years
Patents \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	19 years	19 years

Goodwill and Intangible Assets, net - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2025 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 123,499
Foreign currency translation impact	2,998
Ending balance	$ 126,497

Stockholders’ Equity (Details)	Sep. 30, 2025 vote $ / shares shares	Dec. 31, 2024 $ / shares shares	May 04, 2021 $ / shares
Equity [Abstract]
Common stock, shares authorized (in shares)	320,000,000	320,000,000
Common stock, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, number of votes \| vote	1
Common stock, shares issued (in shares)	127,301,264	124,924,185
Common stock, shares outstanding (in shares)	127,301,264	124,924,185
Preferred stock, shares authorized (in shares)	1,000,000
Preferred stock, par value (in dollars per share) \| $ / shares	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023		122,899,002
Beginning balance at Dec. 31, 2023	$ 59,390	$ 12	$ 541,281	$ (3,036)	$ (478,867)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(679)				(679)
Issuance of common stock pursuant to equity compensation plan (in shares)		843,950
Shares withheld for tax withholdings on vested stock awards (in shares)		(289,533)
Shares withheld for tax withholdings on vested stock awards	(1,005)		(1,005)
Share-based compensation	6,636		6,636
Foreign currency translation adjustments	(1,047)			(1,047)
Ending balance (in shares) at Mar. 31, 2024		123,453,419
Ending balance at Mar. 31, 2024	63,295	$ 12	546,912	(4,083)	(479,546)
Beginning balance (in shares) at Dec. 31, 2023		122,899,002
Beginning balance at Dec. 31, 2023	59,390	$ 12	541,281	(3,036)	(478,867)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(18,768)
Foreign currency translation adjustments	(676)
Ending balance (in shares) at Sep. 30, 2024		124,111,434
Ending balance at Sep. 30, 2024	59,724	$ 12	561,059	(3,712)	(497,635)
Beginning balance (in shares) at Mar. 31, 2024		123,453,419
Beginning balance at Mar. 31, 2024	63,295	$ 12	546,912	(4,083)	(479,546)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	202				202
Issuance of common stock pursuant to equity compensation plan (in shares)		454,362
Shares withheld for tax withholdings on vested stock awards (in shares)		(104,120)
Shares withheld for tax withholdings on vested stock awards	(368)		(368)
Issuance of common stock relating to employee stock purchase plan (in shares)		190,124
Issuance of common stock relating to employee stock purchase plan	378		378
Share-based compensation	6,498		6,498
Foreign currency translation adjustments	(816)			(816)
Ending balance (in shares) at Jun. 30, 2024		123,993,785
Ending balance at Jun. 30, 2024	69,189	$ 12	553,420	(4,899)	(479,344)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(18,291)				(18,291)
Issuance of common stock pursuant to equity compensation plan (in shares)		171,021
Shares withheld for tax withholdings on vested stock awards (in shares)		(53,372)
Shares withheld for tax withholdings on vested stock awards	(73)		(73)
Share-based compensation	7,712		7,712
Foreign currency translation adjustments	1,187			1,187
Ending balance (in shares) at Sep. 30, 2024		124,111,434
Ending balance at Sep. 30, 2024	$ 59,724	$ 12	561,059	(3,712)	(497,635)
Beginning balance (in shares) at Dec. 31, 2024	124,924,185	124,924,185
Beginning balance at Dec. 31, 2024	$ 51,803	$ 12	566,709	(6,953)	(507,965)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(10,096)				(10,096)
Issuance of common stock pursuant to equity compensation plan (in shares)		483,396
Shares withheld for tax withholdings on vested stock awards (in shares)		(161,295)
Shares withheld for tax withholdings on vested stock awards	(250)		(250)
Share-based compensation	3,476		3,476
Foreign currency translation adjustments	1,128			1,128
Ending balance (in shares) at Mar. 31, 2025		125,246,286
Ending balance at Mar. 31, 2025	$ 46,062	$ 13	569,935	(5,825)	(518,061)
Beginning balance (in shares) at Dec. 31, 2024	124,924,185	124,924,185
Beginning balance at Dec. 31, 2024	$ 51,803	$ 12	566,709	(6,953)	(507,965)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(1,415)
Foreign currency translation adjustments	$ 5,178
Ending balance (in shares) at Sep. 30, 2025	127,301,264	127,301,264
Ending balance at Sep. 30, 2025	$ 65,660	$ 13	576,802	(1,775)	(509,380)
Beginning balance (in shares) at Mar. 31, 2025		125,246,286
Beginning balance at Mar. 31, 2025	46,062	$ 13	569,935	(5,825)	(518,061)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	19,712				19,712
Issuance of common stock pursuant to equity compensation plan (in shares)		2,091,026
Shares withheld for tax withholdings on vested stock awards (in shares)		(572,750)
Shares withheld for tax withholdings on vested stock awards	(708)		(708)
Share-based compensation	5,308		5,308
Foreign currency translation adjustments	3,629			3,629
Ending balance (in shares) at Jun. 30, 2025		126,764,562
Ending balance at Jun. 30, 2025	74,003	$ 13	574,535	(2,196)	(498,349)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(11,031)				(11,031)
Issuance of common stock pursuant to equity compensation plan (in shares)		774,465
Shares withheld for tax withholdings on vested stock awards (in shares)		(237,763)
Shares withheld for tax withholdings on vested stock awards	(188)		(188)
Share-based compensation	2,455		2,455
Foreign currency translation adjustments	$ 421			421
Ending balance (in shares) at Sep. 30, 2025	127,301,264	127,301,264
Ending balance at Sep. 30, 2025	$ 65,660	$ 13	$ 576,802	$ (1,775)	$ (509,380)

Description of Business	9 Months Ended
Description of Business	Sep. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business The Beauty Health Company (the “Company”) is a medtech meets beauty company that delivers skin health experiences that help consumers reinvent their relationship with their skin, bodies, and self-confidence. The Company and its subsidiaries design, develop, manufacture, market, and sell esthetic technologies and products. The Company’s brands are pioneers: Hydrafacial in hydradermabrasion; SkinStylus in nanoneedling and microneedling; and Keravive in scalp health. Together, with its powerful global community of estheticians, partners, and consumers, the Company is personalizing skin health for all ages, genders, skin tones, and skin types. Historical Information The Company (f.k.a. Vesper Healthcare Acquisition Corp.) was incorporated in the State of Delaware on July 8, 2020. On May 4, 2021, we consummated the business combination pursuant to that certain Agreement and Plan of Merger, dated December 8, 2020, by and among Vesper Healthcare Acquisition Corp. (“Vesper Healthcare”), Hydrate Merger Sub I, Inc. (“Merger Sub I”), Hydrate Merger Sub II, LLC (“Merger Sub II”), LCP Edge Intermediate, Inc., the indirect parent of HydraFacial LLC, f.k.a. Edge Systems LLC (“Hydrafacial”), and LCP Edge Holdco, LLC (“LCP,” or “Former Parent,” and, in its capacity as the stockholders’ representative, the “Stockholders’ Representative”) (the “Merger Agreement”), which provided for: (a) the merger of Merger Sub I with and into Hydrafacial, with Hydrafacial continuing as the surviving corporation (the “First Merger”), and (b) immediately following the First Merger and as part of the same overall transaction as the First Merger, the merger of Hydrafacial with and into Merger Sub II, with Merger Sub II continuing as the surviving entity (the “Second Merger” and, together with the First Merger, the “Mergers” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). As a result of the First Merger, the Company owns 100% of the outstanding common stock of Hydrafacial and each share of common stock and preferred stock of Hydrafacial was cancelled and converted into the right to receive a portion of the consideration payable in connection with the Mergers. As a result of the Second Merger, the Company owns 100% of the outstanding interests in Merger Sub II. In connection with the closing of the Business Combination (the “Closing”), the Company owns, directly or indirectly, 100% of the stock of Hydrafacial and its subsidiaries and the stockholders of Hydrafacial as of immediately prior to the effective time of the First Merger (the “Hydrafacial Stockholders”) hold a portion of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”). Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. These statements reflect all normal and recurring adjustments which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows of the Company for the interim periods presented. These interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in, or presented as exhibits to, the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2025
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company is required to calculate its interim income tax provision using the estimated annual effective tax rate (“AETR”) method prescribed by Accounting Standards Codification (“ASC”) 740-270, and as such, excludes losses in jurisdictions where the Company cannot benefit in computing its worldwide AETR. A separate AETR is computed and applied to ordinary losses in the U.S. jurisdiction as required by ASC 740-270-30-36(a). For the three and nine months ended September 30, 2025, the Company recorded income tax expense of $0.4 million and $0.3 million, respectively. The AETR differed from the U.S. federal statutory tax rate of 21% due primarily to a full valuation allowance against the Company's U.S. deferred tax assets, income in foreign jurisdictions that are taxed at higher rates than the U.S. federal rate, and the impact of discrete items that may occur in any given year but are not consistent from year to year. For the three and nine months ended September 30, 2024, the Company recorded income tax expense of $1.9 million and $0.9 million, respectively. The estimated worldwide AETR differed from the U.S. federal statutory tax rate of 21% due primarily to a full valuation allowance against the Company's U.S. deferred tax assets, income in foreign jurisdictions that are taxed at higher rates than the U.S. federal rate, and the impact of discrete items that may occur in any given year but are not consistent from year to year. The Company has established a valuation allowance in the U.S. against its deferred tax assets because it is more likely than not that the deferred tax assets will not be realized. In determining whether deferred tax assets are realizable, the Company considers numerous factors including historical profitability, the amount of future taxable income and the existence of taxable temporary differences that can be used to realize deferred tax assets. The Company applies ASC 740, the accounting standard addressing the accounting for uncertainty in income taxes, which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The Company has gross unrecognized tax benefits of $1.5 million and $1.2 million as of September 30, 2025 and December 31, 2024, respectively. On July 4, 2025, the One Big Beautiful Bill Act (the “Act”) was enacted in the United States. The Act includes corporate tax provisions that make 100% bonus depreciation permanent, allow for the expensing of domestic research costs, and modify the business interest expense limitation calculation. The Company has completed its initial assessment of the provisions relevant to its U.S. operations. Based on this assessment, the Act is expected to reduce the Company’s U.S. federal income taxes. The Company has incorporated the Act's changes in its income tax provision for the nine months ended September 30, 2025, which did not have a material impact on the U.S. effective tax rate and net deferred tax assets as the Company maintains a full valuation allowance in the United States.

Balance Sheet Components - Schedule of Accrued Payroll-Related Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Accrued compensation and payroll taxes	$ 12,701	$ 10,708
Accrued sales commissions	4,124	4,784
Accrued benefits	1,934	2,144
Total accrued payroll-related expenses	$ 18,759	$ 17,636

Description of Business (Policies)	9 Months Ended
Description of Business (Policies)	Sep. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. These statements reflect all normal and recurring adjustments which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows of the Company for the interim periods presented. These interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in, or presented as exhibits to, the Company’s Annual Report on Form 10-K for the year ended December 31, 2024
New Accounting Pronouncements	In December 2023, the Financial Standards Accounting Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its annual consolidated financial statement disclosures. In November 2024, the FASB issued ASU 2024-03 “Disaggregation of Income Statement Expenses” which expands interim and annual requirements to disclose about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, which was clarified in ASU 2025-01. The standard allows for early adoption of these requirements. The Company is currently evaluating the potential effect that the updated standard will have on its consolidated financial statement disclosures. In November 2024, the FASB issued ASU 2024-04 “Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments” which is intended to clarify requirements for determining whether certain settlements of convertible debt instruments, including convertible debt instruments with cash conversion features or convertible debt instruments that are not currently convertible, should be accounted for as an induced conversion. ASU 2024-04 is effective for annual periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements and related disclosures. In July 2025, the FASB issued ASU 2025-05 “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets” which simplifies the application of the current expected credit loss model for current accounts receivable and current contract assets under ASC 606. ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, with early adoption permitted, and should be applied prospectively. The Company is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements and related disclosures. In September 2025, the FASB issued ASU 2025-06 “Intangibles: Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software” which modernizes the accounting for internal-use software to current development practices, clarifies when to begin capitalizing costs, and enhances disclosure requirements. ASU 2025-06 is effective for interim and annual periods beginning after December 15, 2027, with early adoption permitted, and should be applied either prospectively, retrospectively, or under a modified prospective transition approach. The Company is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements and related disclosures.

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2025	Nov. 03, 2025
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2025
Document Transition Report	false
Entity File Number	001-39565
Entity Registrant Name	The Beauty Health Company
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1908962
Entity Address, Address Line One	2165 Spring Street
Entity Address, City or Town	Long Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90806
City Area Code	800
Local Phone Number	603-4996
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	SKIN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		127,503,059
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001818093